cocaine use disorder pipeline insight

DelveInsight’s, “Cocaine Use Disorder - Pipeline Insight, 2025,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Cocaine Use Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Cocaine Use Disorder Understanding

Cocaine Use Disorder: Overview

Cocaine is a tropane ester alkaloid found in leaves of the Erythroxylum coca plant, a bush that grows in the Andes Mountain region of South America. Cocaine is a stimulant drug that is frequently abused. Cocaine use can lead to addiction and adverse physical effects, such as stroke and cardiac arrest. Cocaine is classified as a Schedule II medication under the Controlled Substances Act in the United States, which means that it has high potential for abuse but can be administered by a doctor for legitimate medical uses, such as local anesthesia for some eye, ear, and throat surgeries. The short-term physiological effects of cocaine include constricted blood vessels, dilated pupils, and increased temperature, heart rate, and blood pressure. Long-term effects of cocaine use include addiction, irritability and mood disturbances, restlessness, paranoia, and auditory hallucinations. Psychosocial treatments remain the treatments of choice for cocaine use disorder (CUD), with standard approaches including contingency management and cognitive behavioral therapy.

 

"Cocaine Use Disorder - Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cocaine Use Disorder pipeline landscape is provided which includes the disease overview and Cocaine Use Disorder treatment guidelines. The assessment part of the report embraces, in depth Cocaine Use Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cocaine Use Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cocaine Use Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Cocaine Use Disorder.

Cocaine Use Disorder Emerging Drugs Chapters

This segment of the Cocaine Use Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Cocaine Use Disorder Emerging Drugs

 

EMB-001: Embera NeuroTherapeutics

EMB-001 is a patented combination product comprising two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiologic responses to stress in addiction. EMB-001 is thought to act by mechanisms distinct from those of existing addiction treatments and is hypothesized to reduce the increased activity in the stress response system induced by drugs, cues and stressors that contribute to relapse in addiction. Currently, it is in Phase II stage of clinical trial evaluation to treat Cocaine Use Disorder.

 

NS2359: Saniona

NS2359 is a triple reuptake inhibitor, which blocks the reuptake of dopamine, norepinephrine, and serotonin in a similar manner to cocaine. However, NS2359 dissociates slowly from these transporters and has a long human half-life (up to 10 days) which makes frequent dosing unnecessary. NS2359s pharmacological profile means that it may be able to reduce cocaine withdrawal symptoms, reduce cocaine craving and reduce cocaine-induced euphoria. In preclinical trials, NS2359 has been shown to reduce the reinforcing effects of cocaine and may have effects on cue induced drug craving. Furthermore, human trials with NS2359 have shown that NS2359 has little abuse potential and does not have adverse interactions with cocaine. Thus, NS2359 is a very promising medication for the treatment of cocaine dependence. A Phase II clinical trial evaluating NS2359 has been completed for the treatment of Cocaine Dependence.

 

KNX100: Kinoxis Theraputics

Kinoxis’ lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms. KNX100 has a novel, undisclosed mechanism of action and is nearing Phase I clinical trials. The company is also exploring other indications for its lead compound, KNX100, as promising preclinical results have been achieved in animal models of cocaine, methamphetamine, nicotine, and alcohol use disorders, as well as models of agitation and aggression.

Further product details are provided in the report……..

Cocaine Use Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Cocaine Use Disorder drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Cocaine Use Disorder

There are approx. 12+ key companies which are developing the therapies for Cocaine Use Disorder. The companies which have their Cocaine Use Disorder drug candidates in the most advanced stage, i.e. phase II include, Embera NeuroTherapeutics.

Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Cocaine Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Molecule Type

 

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Explore the evolving Cocaine Use Disorder Market trends, key players, and future outlook.

Cocaine Use Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cocaine Use Disorder therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cocaine Use Disorder drugs.

Cocaine Use Disorder Report Insights

• Cocaine Use Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cocaine Use Disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are working to drive the Cocaine Use Disorder market?
• How many Cocaine Use Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cocaine Use Disorder?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cocaine Use Disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cocaine Use Disorder and their status?
• What are the key designations that have been granted to the emerging drugs?